Eli Lilly and Company announced it will present new clinical data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Annual Meeting, scheduled for October 17-21 in Berlin, Germany. A key highlight will be the first-ever presentation of the primary overall survival analysis from the landmark seven-year monarchE study of Verzenio (abemaciclib) in patients with HR+, HER2-, node-positive, high-risk early breast cancer. This data is highly anticipated as it could further solidify Verzenio's role in the curative setting for this patient population. In addition to the Verzenio data, Lilly will present findings for several investigational therapies, including olomorasib for KRAS G12C-mutant non-small cell lung cancer, LY4064809 for PIK3CA-mutant advanced breast cancer, and other pipeline programs targeting various cancers. The breadth of the data being presented underscores the company's commitment to advancing its oncology pipeline.